_______________________________________________________________________________________________________ πŸ“… November 17, 2026 | πŸ•’ 11 AM Eastern Time US | πŸ•’ 4 PM GMT | ⏳ 90 Minutes


$240 
  • Product ID: FDB3245

Registration Options (LIVE ONLY): *
COMBO: Add 30-Day Complimentary Recording Access: *

Learn More


This course helps laboratories establish consistent, scientifically justified controls for exceptions, invalidations, and retesting while strengthening traceability, electronic record oversight, and inspection readiness during regulatory scrutiny.


Laboratory exceptions, invalidations, out-of-specification results, and retesting decisions are closely examined during regulatory inspections because weak controls can permit undocumented judgment, selective reporting, or manipulation of analytical data. Data integrity therefore depends on clear governance for how atypical, OOS, OOT, and deviation results are reviewed, when results may be invalidated, and when additional testing is scientifically justified, documented, traceable, and consistently governed.


This webinar examines how laboratories can structure data integrity controls around exception handling, invalidation, retesting, audit trail review, and electronic records. Participants will consider ALCOA+ principles, documentation of investigations and decisions, root cause and CAPA considerations, risk-based review of chromatography and analytical data, and controls that prevent testing into compliance. The discussion also addresses inspection readiness under FDA, MHRA, WHO, PIC/S, 21 CFR Part 11, and EU GMP Annex 11 expectations, including the roles of analysts, supervisors, QA, and laboratory management.

| WHY YOU SHOULD ATTEND

Make More Consistent Invalidation and Retesting Decisions

Build clearer criteria for deciding when laboratory results may be invalidated, when retesting is scientifically justified, and when additional investigation is required. Applying consistent controls to OOS, OOT, atypical results, and deviations helps reduce selective reporting, unsupported decisions, and practices that regulators may interpret as testing into compliance.


Strengthen Traceability Behind Laboratory Decisions

Strengthen the records and oversight surrounding laboratory decisions through ALCOA+ principles, audit trail review, electronic record controls, defined responsibilities, and documented rationale. This supports more transparent investigations and makes it easier to reconstruct who made key decisions, what evidence was considered, and how conclusions were reached during inspections.

| AREAS COVERED

  • Governance of OOS, OOT, atypical results, and laboratory deviations
  • Scientifically justified criteria for result invalidation and retesting
  • Controls preventing selective reporting and testing into compliance
  • ALCOA+ principles for laboratory investigations and decision records
  • Audit trail review and electronic record controls under 21 CFR Part 11
  • EU GMP Annex 11 data integrity expectations for laboratory systems
  • Root cause analysis and CAPA considerations for laboratory events
  • Risk-based review of chromatography and analytical data

| WHO SHOULD ATTEND

  • Quality Assurance
  • CSV/CSA Teams
  • IT and Digital Transformation Leaders
  • Regulatory Affairs
  • Manufacturing
  • Operations
  • LIMS Administrators
  • Clinical Systems
  • Data Integrity Specialists
  • Cybersecurity and AI Governance Teams
  • Compliance
  • Auditors
  • Vendors and consultants supporting GxP systems